Clinical Trials Logo

Filter by:
NCT ID: NCT04939428 Completed - Clinical trials for Coronavirus Disease (COVID-19)

Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)

MOVe-AHEAD
Start date: August 11, 2021
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess if the study medication (molnupiravir, MK-4482) will prevent symptomatic coronavirus disease 2019 (COVID-19) in adults who live with someone with confirmed COVID-19 infection. This is a phase 3, multicenter, randomized, double-blind, placebo-controlled study; half of the study participants will receive molnupiravir twice daily by mouth and the other half will receive a placebo. The primary objectives of the study are to determine if molnupiravir prevents symptomatic COVID-19 disease and to evaluate its safety and tolerability. All participants who develop COVID-19 during the study are still eligible for any COVID-19 treatment recommended by their doctor.

NCT ID: NCT04939181 Completed - Basketball Player Clinical Trials

Non-invasive Neuromodulation NESA in Neuroefficiency in Basketball Players

Start date: May 1, 2021
Phase: N/A
Study type: Interventional

Competitive team sports calendars are becoming increasingly compressed, generating changes in the effort-recovery cycle. Given this new situation, it seems necessary to analyze how it affects the physiological and performance level of semi-professional players, as well as how to observe if the non-invasive neuromodulation technique NESA helps the neuroefficiency and concentration values of said players.

NCT ID: NCT04938934 Completed - Healthy Clinical Trials

Conditioning Effect of Previous Symptoms on the Responses to Meal Ingestion

Start date: June 24, 2021
Phase: N/A
Study type: Interventional

Meal ingestion induces sensations that are influenced by a series of conditioning factors. Aim: to determine the conditioning effect of previous digestive symptoms to a standardized probe meal. Controlled randomized parallel study in healthy subjects on the conditioning effect of previous digestive symptoms on the responses to a comfort meal. Digestive symptoms will be induced by lipid (or sham) infusion into the intestine. On three separate days, digestive sensations (satiety, abdominal bloating, digestive well-being, mood, discomfort) in response to a comfort meal will be measured before, during and after the intervention. Primary outcome: effect of conditioning on the sensation of digestive well-being measured by -5 to +5 scale after a comfort meal. Secondary aim: effect of conditioning on abdominal on homeostatic sensations (satiety, fullness, discomfort, nausea). Participants (16 women, 8 in the intestinal infusion and 8 in the sham intervention) will be instructed to eat a standard dinner the day before, to consume a standard breakfast at home after overnight fast, and to report to the laboratory, where the comfort meal will be administered 4 h after breakfast. Studies will be conducted in a quiet, isolated room. On each study day, participants will be intubated with a nasoduodenal feeding tube under fluoroscopic control for lipids or sham infusion. A comfort meal will be administered and perception of digestive sensations will be measured at 5 min intervals 10 min before and 20 min after ingestion and at 10 min intervals up to 60 min after the probe meal.

NCT ID: NCT04938427 Completed - Clinical trials for Lennox Gastaut Syndrome (LGS)

A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

Start date: November 8, 2021
Phase: Phase 3
Study type: Interventional

The aims of the study are: - to learn if soticlestat, when given as add-on therapy, reduces the number of major motor drop seizures in children, teenagers, and adults with Lennox-Gastaut Syndrome. - to assess the safety profile of soticlestat when given in combination with other therapies. Participants will receive their standard antiseizure therapy, plus either tablets of soticlestat or placebo. A placebo looks just like soticlestat but will not have any medicine in it. Participants will take soticlestat or placebo for 16 weeks, followed by a gradual dose reduction for 1 week. Then, participants will be followed up for 2 weeks.

NCT ID: NCT04937777 Completed - AL Amyloidosis Clinical Trials

A Study on the Management and Outcome of Patients With Systemic AL Amyloidosis in Europe

Start date: April 23, 2019
Phase:
Study type: Observational

This is a retrospective, observational, multicenter study to collect Real-World Evidence (RWE) data on systemic AL-AMY patients in Europe. Data from paper/electronic medical records and/or electronic databases from key reference centers in Europe will be used. Data will either be entered by the site staff in the electronic Case Report Form (eCRF) or, where feasible, transferred directly, always in accordance to local regulations.

NCT ID: NCT04937725 Completed - Multiple Sclerosis Clinical Trials

Reading Problems Associated With Central Nervous System (CNS) Pathologies.

Start date: June 1, 2021
Phase:
Study type: Observational

This project aims to analyse eye movements, their alterations and influence in reading performance in patients with acquired CNS diseases and compare them with people of the same age, without neurological or ocular pathology and with normal reading speed and pattern. The exploration is focused on the oculomotor system in patients with CNS diseases, even without involvement of the primary visual pathway, and reveals more involvement than the one obtained by a simple ophthalmological examination.

NCT ID: NCT04937556 Completed - Covid19 Clinical Trials

Evaluation of a Probiotic Supplementation in the Immune Response of Participants With COVID-19 (Coronavirus Disease).

PROVID
Start date: October 25, 2021
Phase: N/A
Study type: Interventional

An interventional, randomized, double-blind, placebo-controlled study will be conducted to investigate the effect of a probiotic strain on the immune response in participants positive for SARS-CoV-2 infection. The study duration will be 28 days, which includes 4 weeks product administration. Participants will be randomized assigned to one of the two study groups: the control group with placebo consumption and a probiotic consumption group.

NCT ID: NCT04936139 Completed - Cancer Clinical Trials

Art Therapy Effectiveness in the Level of Anxiety and Depression of Cancer Patients

ATANDEC
Start date: February 21, 2021
Phase: N/A
Study type: Interventional

Having a diagnosis of cancer leaves a great emotional impact when it comes to strategies for coping with illness and life after illness. Participation in an art therapy program to forge and improve the emotional well-being is considered. Art therapy can be an effective intervention to help cancer patients lower their levels of anxiety and depression and in return improve their quality of life and their ability to cope with the disease.

NCT ID: NCT04935398 Completed - Clinical trials for Tenopathy; Lower Limb

Efficacy of Manual Therapy Combined With an Exercise Programme VS Combined Electrotherapy on Football Players With Adductor Tendinopathy

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

Background: Groin pain associated with adductor tendinopathy is the second cause of muscle pathology in a football player (20%), so a good treatment taking into account both internal and external factors that may influence the pathology of our patient, would be the key to an improvement in the symptoms he may have. Material and methods: Firstly, the pain threshold is measured by performing the Copenhagen compression test, and in a palpation at the proximal level of the adductors, the hip joint range (ROM) is measured and the HAGOS questionnaire is passed. Then, a sample of 20 participants (N = 20) is selected and randomly divided into two groups, a control group of 10 participants (n = 10), with a treatment based on electrotherapy combined with an exercise programme; and an experimental group of 10 participants (n = 10) with a treatment based on manual therapy combined with an exercise programme. Finally, they performed all measurements.

NCT ID: NCT04933565 Completed - Healthy Volunteers Clinical Trials

First in Human Study of ORG-129 in Healthy Volunteers

Start date: June 1, 2021
Phase: Phase 1
Study type: Interventional

The current study is performed to characterize the safety, tolerability and pharmacokinetics of ORG-129 after oral intake in healthy male and female volunteers after single ascending and multiple ascending doses.